AcquisitionOther

Tempest Therapeutics, Inc. acquired CAR T-cell therapy assets

Name: Tempest Therapeutics, Inc. acquired CAR T-cell therapy assets
Start: 2026-02-06

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Tempest Therapeutics, Inc. -> CAR T-cell therapy assets · 8,268,495 shares of common stock

Acquire autologous and allogeneic CAR T-cell therapy candidates.